Literature DB >> 1411766

Delay in diagnosis of intradural spinal tumors.

M Peña1, C S Galasko, J L Barrie.   

Abstract

Fifty-seven patients with primary intradural spinal tumors operated on in North Manchester and Salford between 1978 and 1988 were reviewed retrospectively. The commonest diagnoses were meningioma and nerve sheath cell tumors (neurilemmomas and neurofibromas). The median delay in diagnosis was 2.5 years (range 3 days to 24 years). Fifty-eight percent were initially referred to orthopaedic surgeons and 95% percent to specialties other than neurosurgery. The commonest presenting symptom was back pain, but later neurologic and urinary symptoms came to predominate. Eighty-eight percent are disease-free at a mean follow-up of 5.7 years. Symptoms were partially or completely relieved in the majority of patients. Delay in diagnosis of these tumors arises from failure to consider the diagnosis in patients with longstanding back pain or neurologic problems.

Entities:  

Mesh:

Year:  1992        PMID: 1411766     DOI: 10.1097/00007632-199209000-00017

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  3 in total

1.  Spinal meningiomas: critical review of 131 surgically treated patients.

Authors:  I Erol Sandalcioglu; Anja Hunold; Oliver Müller; Hischam Bassiouni; Dietmar Stolke; Siamak Asgari
Journal:  Eur Spine J       Date:  2008-05-15       Impact factor: 3.134

2.  Spinal cord meningioma: a treatable cause of paraplegia.

Authors:  Manoj K Mittal; Alejandro A Rabinstein
Journal:  J Clin Med Res       Date:  2012-07-20

3.  Surgical outcome and prognostic factors in spinal cord ependymoma: a single-center, long-term follow-up study.

Authors:  Oliver Gembruch; Mehdi Chihi; Merle Haarmann; Ahmet Parlak; Marvin Darkwah Oppong; Laurèl Rauschenbach; Anna Michel; Ramazan Jabbarli; Yahya Ahmadipour; Ulrich Sure; Philipp Dammann; Neriman Özkan
Journal:  Ther Adv Neurol Disord       Date:  2021-11-10       Impact factor: 6.570

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.